What have we learned from the real-world efficacy of FFA in DS and LGS? A post-marketing study in clinical practice-Reference-Cited by-同舟云学术

What have we learned from the real-world efficacy of FFA in DS and LGS? A post-marketing study in clinical practice

Published:2024-02 Issue: Volume:151 Page:109620
ISSN:1525-5050
Container-title:Epilepsy & Behavior
language:en
Short-container-title:Epilepsy & Behavior

Author:

Valls Carbó Adrián,Beltrán Álvaro,Sánchez-Miranda Román Irene,Cabal Borja^ORCID,Gómez-Porro Pablo^ORCID,Aledo-Serrano Ángel,López Sobrino Gloria,Ayuga Fernando,Gómez Eguilaz María,Gil-Nagel Antonio^ORCID

Funder

UCB Pharma

Publisher

Elsevier BV

Reference16 articles.

1. UCB I. FINTEPLA® (fenfluramine) oral solution [prescribing information]. Smyrna, GA March 2023.

2. Zogenix ROI Limited. Fintepla 2.2 mg/mL oral solution [summary of product characteristics]. Dublin, IE: Zogenix ROI Limited; April 20 2023.

3. UCB Japan Co. LTD. Fintepla Oral Solution 2.2 mg/mL [prescribing information]. Tokyo, Japan September 26 2022.

4. Fenfluramine for treatment-resistant seizures in patients with Dravet syndrome receiving stiripentol-inclusive regimens: a randomized clinical trial;Nabbout;JAMA Neurol,2020

5. Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial;Lagae;Lancet,2019

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fenfluramine treatment in pediatric patients with Dravet syndrome reduces seizure burden and overall healthcare costs: A retrospective and observational real‐world study;Epilepsia Open;2024-08-14

2. Practical considerations for the use of fenfluramine to manage patients with Dravet syndrome or Lennox–Gastaut syndrome in clinical practice;Epilepsia Open;2024-07-04